Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01405742 · ClinicalTrials.gov registry record · Phase 3
Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A
A Phase 3 study, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT01405742 is a Phase 3 study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 4 participants.
The verdict
NCT01405742, a Phase 3 study, was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this pilot R34 trial is to determine the feasibility of a large single dose Phase III study of hemophilia adult prophylaxis comparing once weekly with thrice-weekly recombinant factor VIII. Efficacy will measured by bleeding frequency, factor usage, joint range of motion, cost, quality-of-life, F.VIII level, and inter-dose hypocoagulability by thrombin generation. Safety will be measured by inhibitor formation and bleeding events unresponsive to up to two rescue doses.
Interventions
- DRUG rF.VIII
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01405742
The ClinicalTrials.gov registry entry for NCT01405742 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rF.VIII is the first listed.
NCT01405742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01405742 about?
NCT01405742 is a clinical study titled "Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A". The purpose of this pilot R34 trial is to determine the feasibility of a large single dose Phase III study of hemophilia adult prophylaxis comparing once weekly with thrice-weekly recombinant factor VIII. Efficacy will measured by bleeding frequency, factor usage, joint range of motion, cost, qualit...
What is the current status of trial NCT01405742?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2012-07. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01405742?
The interventions under investigation include: rF.VIII (DRUG).
Who is sponsoring clinical trial NCT01405742?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.